Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Victor De Gruttola, D.Sc.

Title
Institution
Department
Address
Phone
Profile Picture

Overview
Dr. De Gruttola's research activities focus on developments of statistical methods required for appropriate public health response to the AIDS epidemic. The aspects of the epidemic on which he has worked include transmission of the Human Immunodeficiency Virus (HIV), natural history of infection with HIV, and clinical research on AIDS therapies.

This work involves not only statistical methodology, but also public health surveillance systems, medical issues surrounding HIV infection, and concerns of communities most affected by the epidemic. The goals include forecasting future AIDS incidence, developing strategies for clinical research on HIV infection, and evaluating the public health impact of antiviral treatment. The statistical issues on which Dr. De Gruttola has been engaged include evaluating the degree to which the treatment response of markers of HIV infection constitute adequate evidence for clinical efficacy. He has also worked on projections of AIDS incidence using data from the New York City Health Department. A special focus of this work was estimation of the risk that children of HIV-infected mothers would develop AIDS in the first 10 years of life using data combined from a variety of sources.

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R37AI051164 (DEGRUTTOLA, VICTOR GERARD) Dec 1, 2015 - Nov 30, 2019
    NIH/NIAID
    Methods to Advance the HIV Prevention Research Agenda
    Role: Principal Investigator
  2. R01AI051164 (DEGRUTTOLA, VICTOR GERARD) Mar 1, 2002 - Nov 30, 2011
    NIH/NIAID
    Methods for Long-Term Follow-Up of HIV-Infected Patients
    Role: Principal Investigator
  3. U01AI038855 (HUGHES, MICHAEL DAVID) Jan 1, 1996 - Dec 31, 2006
    NIH
    STATISTICAL AND DATA MANAGEMENT CENTER
    Role: Co-Principal Investigator
  4. R29AI028905 (DEGRUTTOLA, VICTOR GERARD) Dec 1, 1989 - Nov 30, 1994
    NIH/NIAID
    STATISTICAL MODELING OF PROGRESSION OF HIV INFECTION
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. De Gruttola V, Goyal R, Martin NK. Discussion of article by Ellenberg and Morris. Stat Med. 2021 May 20; 40(11):2511-2512. PMID: 33963584.
    Citations:    Fields:    
  2. Wu PZ, O'Malley JT, de Gruttola V, Liberman MC. Primary Neural Degeneration in Noise-Exposed Human Cochleas: Correlations with Outer Hair Cell Loss and Word-Discrimination Scores. J Neurosci. 2021 Apr 20. PMID: 33883202.
    Citations:    Fields:    
  3. Goyal R, De Gruttola V. Investigation of patient-sharing networks using a Bayesian network model selection approach for congruence class models. Stat Med. 2021 Apr 02. PMID: 33811360.
    Citations:    Fields:    
  4. Mepani AM, Verhulst S, Hancock KE, Garrett M, Vasilkov V, Bennett K, de Gruttola V, Liberman MC, Maison SF. Envelope following responses predict speech-in-noise performance in normal-hearing listeners. J Neurophysiol. 2021 04 01; 125(4):1213-1222. PMID: 33656936.
    Citations:    Fields:    
  5. Goyal R, Hotchkiss J, Schooley RT, De Gruttola V, Martin NK. Evaluation of SARS-CoV-2 transmission mitigation strategies on a university campus using an agent-based network model. Clin Infect Dis. 2021 Jan 19. PMID: 33462589.
    Citations: 2     Fields:    
  6. Hassan A, De Gruttola V, Hu YW, Sheng Z, Poortinga K, Wertheim JO. The Relationship Between the Human Immunodeficiency Virus-1 Transmission Network and the HIV Care Continuum in Los Angeles County. Clin Infect Dis. 2020 12 03; 71(9):e384-e391. PMID: 32020172.
    Citations:    Fields:    Translation:HumansCells
  7. Rennert L, Heo M, Litwin AH, De Gruttola V. Accounting for Confounding by Time, Early Intervention Adoption, and Time-Varying Effect Modification in the Design and Analysis of Stepped-Wedge Designs: Application to a Proposed Study Design to Reduce Opioid-Related Mortality. Res Sq. 2020 Nov 12. PMID: 33200125.
    Citations:    
  8. Montazeri H, Little S, Mozaffarilegha M, Beerenwinkel N, DeGruttola V. Bayesian reconstruction of transmission trees from genetic sequences and uncertain infection times. Stat Appl Genet Mol Biol. 2020 Oct 21. PMID: 33085643.
    Citations:    Fields:    
  9. Wang R, DeGruttola V, Lei Q, Mayer KH, Redline S, Hazra A, Mora S, Willett WC, Ganmaa D, Manson JE. The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design. Contemp Clin Trials. 2021 01; 100:106176. PMID: 33045402.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  10. Addington EL, Javandel S, De Gruttola V, Paul R, Milanini B, Ances BM, Moskowitz JT, Valcour V. Mindfulness-based stress reduction for HIV-associated neurocognitive disorder: Rationale and protocol for a randomized controlled trial in older adults. Contemp Clin Trials. 2020 11; 98:106150. PMID: 32942053.
    Citations:    Fields:    
  11. Molebatsi K, Gabaitiri L, Mokgatlhe L, Moyo S, Gaseitsiwe S, Wirth KE, DeGruttola V, Tchetgen Tchetgen E. Efficient estimation of human immunodeficiency virus incidence rate using a pooled cross-sectional cohort study design. Stat Med. 2020 10 30; 39(24):3255-3271. PMID: 32875624.
    Citations:    Fields:    
  12. Rennert L, Heo M, Litwin AH, De Gruttola V. Accounting for external factors and early intervention adoption in the design and analysis of stepped-wedge designs: Application to a proposed study design to reduce opioid-related mortality. medRxiv. 2020 Jul 29. PMID: 32766601.
    Citations:    
  13. Wu PZ, O'Malley JT, de Gruttola V, Liberman MC. Age-Related Hearing Loss Is Dominated by Damage to Inner Ear Sensory Cells, Not the Cellular Battery That Powers Them. J Neurosci. 2020 08 12; 40(33):6357-6366. PMID: 32690619.
    Citations: 7     Fields:    Translation:HumansCells
  14. Ozga F, Onnela JP, DeGruttola V. Bayesian method for inferring the impact of geographical distance on intensity of communication. Sci Rep. 2020 07 16; 10(1):11775. PMID: 32678148.
    Citations:    Fields:    Translation:Humans
  15. Grant KJ, Mepani AM, Wu P, Hancock KE, de Gruttola V, Liberman MC, Maison SF. Electrophysiological markers of cochlear function correlate with hearing-in-noise performance among audiometrically normal subjects. J Neurophysiol. 2020 08 01; 124(2):418-431. PMID: 32639924.
    Citations: 2     Fields:    
  16. Ogburn EL, Bierer BE, Brookmeyer R, Choirat C, Dean NE, De Gruttola V, Ellenberg SS, Halloran ME, Hanley DF, Lee JK, Wang R, Scharfstein DO. Aggregating data from COVID-19 trials. Science. 2020 06 12; 368(6496):1198-1199. PMID: 32527823.
    Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
  17. Novitsky V, Zahralban-Steele M, Moyo S, Nkhisang T, Maruapula D, McLane MF, Leidner J, Bennett K, Wirth KE, Gaolathe T, Kadima E, Chakalisa U, Pretorius Holme M, Lockman S, Mmalane M, Makhema J, Gaseitsiwe S, DeGruttola V, Essex M. Mapping of HIV-1C Transmission Networks Reveals Extensive Spread of Viral Lineages Across Villages in Botswana Treatment-as-Prevention Trial. J Infect Dis. 2020 11 15; 222(10):1670-1680. PMID: 32492145.
    Citations: 1     Fields:    Translation:HumansCells
  18. Wirth KE, Gaolathe T, Pretorius Holme M, Mmalane M, Kadima E, Chakalisa U, Manyake K, Matildah Mbikiwa A, Simon SV, Letlhogile R, Mukokomani K, van Widenfelt E, Moyo S, Bennett K, Leidner J, Powis KM, Lebelonyane R, Alwano MG, Jarvis J, Dryden-Peterson SL, Kgathi C, Moore J, Bachanas P, Raizes E, Abrams W, Block L, Sento B, Novitsky V, El-Halabi S, Marukutira T, Mills LA, Sexton C, Pals S, Shapiro RL, Wang R, Lei Q, DeGruttola V, Makhema J, Essex M, Lockman S, Tchetgen Tchetgen EJ. Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial. Lancet HIV. 2020 06; 7(6):e422-e433. PMID: 32504575.
    Citations:    Fields:    Translation:HumansCellsPHPublic Health
  19. Martin N, Schooley RT, De Gruttola V. Modelling testing frequencies required for early detection of a SARS-CoV-2 outbreak on a university campus. medRxiv. 2020 Jun 01. PMID: 32577676.
    Citations:    
  20. Wang R, Bing A, Wang C, Hu Y, Bosch RJ, DeGruttola V. A flexible nonlinear mixed effects model for HIV viral load rebound after treatment interruption. Stat Med. 2020 07 10; 39(15):2051-2066. PMID: 32293756.
    Citations:    Fields:    
  21. Dean NE, Gsell PS, Brookmeyer R, Crawford FW, Donnelly CA, Ellenberg SS, Fleming TR, Halloran ME, Horby P, Jaki T, Krause PR, Longini IM, Mulangu S, Muyembe-Tamfum JJ, Nason MC, Smith PG, Wang R, Henao-Restrepo AM, De Gruttola V. Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. N Engl J Med. 2020 04 02; 382(14):1366-1369. PMID: 32242365.
    Citations: 21     Fields:    Translation:HumansPHPublic Health
  22. Parthasarathy A, Hancock KE, Bennett K, DeGruttola V, Polley DB. Bottom-up and top-down neural signatures of disordered multi-talker speech perception in adults with normal hearing. Elife. 2020 01 21; 9. PMID: 31961322.
    Citations: 7     Fields:    
  23. Mepani AM, Kirk SA, Hancock KE, Bennett K, de Gruttola V, Liberman MC, Maison SF. Middle Ear Muscle Reflex and Word Recognition in "Normal-Hearing" Adults: Evidence for Cochlear Synaptopathy? Ear Hear. 2020 Jan/Feb; 41(1):25-38. PMID: 31584501.
    Citations: 4     Fields:    
  24. Fernandez KA, Guo D, Micucci S, De Gruttola V, Liberman MC, Kujawa SG. Noise-induced Cochlear Synaptopathy with and Without Sensory Cell Loss. Neuroscience. 2020 02 10; 427:43-57. PMID: 31887361.
    Citations: 7     Fields:    Translation:AnimalsCellsPHPublic Health
  25. Kennedy-Shaffer L, de Gruttola V, Lipsitch M. Novel methods for the analysis of stepped wedge cluster randomized trials. Stat Med. 2020 03 30; 39(7):815-844. PMID: 31876979.
    Citations: 7     Fields:    
  26. Makhema J, Wirth KE, Pretorius Holme M, Gaolathe T, Mmalane M, Kadima E, Chakalisa U, Bennett K, Leidner J, Manyake K, Mbikiwa AM, Simon SV, Letlhogile R, Mukokomani K, van Widenfelt E, Moyo S, Lebelonyane R, Alwano MG, Powis KM, Dryden-Peterson SL, Kgathi C, Novitsky V, Moore J, Bachanas P, Abrams W, Block L, El-Halabi S, Marukutira T, Mills LA, Sexton C, Raizes E, Gaseitsiwe S, Bussmann H, Okui L, John O, Shapiro RL, Pals S, Michael H, Roland M, DeGruttola V, Lei Q, Wang R, Tchetgen Tchetgen E, Essex M, Lockman S. Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. N Engl J Med. 2019 07 18; 381(3):230-242. PMID: 31314967.
    Citations: 43     Fields:    Translation:HumansPHPublic Health
  27. Dean NE, Gsell PS, Brookmeyer R, De Gruttola V, Donnelly CA, Halloran ME, Jasseh M, Nason M, Riveros X, Watson CH, Henao-Restrepo AM, Longini IM. Design of vaccine efficacy trials during public health emergencies. Sci Transl Med. 2019 07 03; 11(499). PMID: 31270270.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  28. Kobe J, Talbot O, Chen I, Eshleman SH, Cummings V, Wheeler D, Mayer KH, DeGruttola V. Short Communication: Viral Genetic Linkage Analysis Among Black Men Who Have Sex With Men (HIV Prevention Trials Network 061). AIDS Res Hum Retroviruses. 2019 05; 35(5):434-436. PMID: 30638029.
    Citations:    Fields:    Translation:HumansCells
  29. Lockman S, De Gruttola V. Outcomes Following Pregnancy Conception on Antiretroviral Therapy: A Call for More Data. Clin Infect Dis. 2019 01 07; 68(2):280-281. PMID: 30137330.
    Citations:    Fields:    Translation:Humans
  30. Wu PZ, Liberman LD, Bennett K, de Gruttola V, O'Malley JT, Liberman MC. Primary Neural Degeneration in the Human Cochlea: Evidence for Hidden Hearing Loss in the Aging Ear. Neuroscience. 2019 05 21; 407:8-20. PMID: 30099118.
    Citations: 44     Fields:    Translation:HumansCellsPHPublic Health
  31. Oldenburg CE, Seage GR, Tanser F, De Gruttola V, Mayer KH, Mimiaga MJ, Bor J, Bärnighausen T. Antiretroviral Therapy and Mortality in Rural South Africa: A Comparison of Causal Modeling Approaches. Am J Epidemiol. 2018 08 01; 187(8):1772-1779. PMID: 29584868.
    Citations: 3     Fields:    Translation:Humans
  32. Gurmu Y, Qian J, De Gruttola V. A Sexual Partnership Duration: Characterizing Sampling Conditions That Permit unbiased Estimation of Survivorship and Effect on It of Covariates. Res Rev J Stat Math Sci. 2018 Jun; 4(1):22-35. PMID: 30264038.
    Citations:    
  33. Oldenburg CE, Bor J, Harling G, Tanser F, Mutevedzi T, Shahmanesh M, Seage GR, De Gruttola V, Mimiaga MJ, Mayer KH, Pillay D, Bärnighausen T. Impact of early antiretroviral therapy eligibility on HIV acquisition: household-level evidence from rural South Africa. AIDS. 2018 03 13; 32(5):635-643. PMID: 29334546.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  34. Novitsky V, Prague M, Moyo S, Gaolathe T, Mmalane M, Yankinda EK, Chakalisa U, Lebelonyane R, Khan N, Powis KM, Widenfelt E, Gaseitsiwe S, Dryden-Peterson SL, Holme MP, De Gruttola V, Bachanas P, Makhema J, Lockman S, Essex M. High HIV-1 RNA Among Newly Diagnosed People in Botswana. AIDS Res Hum Retroviruses. 2018 03; 34(3):300-306. PMID: 29214845.
    Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
  35. Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, Cooper BS, DeGruttola V, Hughes JP, Lessler J, Lofgren ET, Longini IM, Onnela JP, Özler B, Seage GR, Smith TA, Vespignani A, Vynnycky E, Lipsitch M. Simulations for designing and interpreting intervention trials in infectious diseases. BMC Med. 2017 12 29; 15(1):223. PMID: 29287587.
    Citations: 16     Fields:    Translation:Humans
  36. Goyal R, De Gruttola V. Inference on network statistics by restricting to the network space: applications to sexual history data. Stat Med. 2018 Jan 30; 37(2):218-235. PMID: 28745004.
    Citations:    Fields:    Translation:Humans
  37. Zhao R, Catalano P, DeGruttola VG, Michor F. Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model. PLoS One. 2017; 12(7):e0180756. PMID: 28723910.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  38. Wang R, De Gruttola V. The use of permutation tests for the analysis of parallel and stepped-wedge cluster-randomized trials. Stat Med. 2017 Aug 15; 36(18):2831-2843. PMID: 28464567.
    Citations: 10     Fields:    Translation:Humans
  39. Macatangay BJ, Yang M, Sun X, Morton J, De Gruttola V, Little S, Hogan C, Rinaldo CR. Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217. . 2017 05 01; 75(1):137-141. PMID: 28198712.
    Citations: 5     Translation:HumansCells
  40. Balzer L, Staples P, Onnela JP, DeGruttola V. Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial. Clin Trials. 2017 Apr; 14(2):201-210. PMID: 28124579.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  41. Harling G, Wang R, Onnela JP, De Gruttola V. Leveraging contact network structure in the design of cluster randomized trials. Clin Trials. 2017 Feb; 14(1):37-47. PMID: 27798376.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  42. Oldenburg CE, Bärnighausen T, Tanser F, Iwuji CC, De Gruttola V, Seage GR, Mimiaga MJ, Mayer KH, Pillay D, Harling G. Reply to Cohen et al. Clin Infect Dis. 2016 12 15; 63(12):1680. PMID: 27694482.
    Citations:    Fields:    
  43. Abuelezam NN, McCormick AW, Fussell T, Afriyie AN, Wood R, DeGruttola V, Freedberg KA, Lipsitch M, Seage GR. Can the Heterosexual HIV Epidemic be Eliminated in South Africa Using Combination Prevention? A Modeling Analysis. Am J Epidemiol. 2016 08 01; 184(3):239-48. PMID: 27416841.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  44. Oldenburg CE, Bärnighausen T, Tanser F, Iwuji CC, De Gruttola V, Seage GR, Mimiaga MJ, Mayer KH, Pillay D, Harling G. Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa. Clin Infect Dis. 2016 08 15; 63(4):548-54. PMID: 27208044.
    Citations: 12     Fields:    Translation:HumansCells
  45. Prague M, Wang R, Stephens A, Tchetgen Tchetgen E, DeGruttola V. Accounting for interactions and complex inter-subject dependency in estimating treatment effect in cluster-randomized trials with missing outcomes. Biometrics. 2016 12; 72(4):1066-1077. PMID: 27060877.
    Citations: 5     Fields:    Translation:Humans
  46. Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, Yankinda EK, Lei Q, Mmalane M, Novitsky V, Okui L, van Widenfelt E, Powis KM, Khan N, Bennett K, Bussmann H, Dryden-Peterson S, Lebelonyane R, El-Halabi S, Mills LA, Marukutira T, Wang R, Tchetgen EJ, DeGruttola V, Essex M, Lockman S. Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016 May; 3(5):e221-30. PMID: 27126489.
    Citations: 82     Fields:    Translation:Humans
  47. Liu SH, Erion G, Novitsky V, De Gruttola V. Viral Genetic Linkage Analysis in the Presence of Missing Data. PLoS One. 2015; 10(8):e0135469. PMID: 26301919.
    Citations: 1     Fields:    Translation:HumansCells
  48. Wirth KE, Agniel D, Barr CD, Austin MD, DeGruttola V. A composite likelihood approach for estimating HIV prevalence in the presence of spatial variation. Stat Med. 2015 Dec 10; 34(28):3750-9. PMID: 26215657.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  49. Goyal R, De Gruttola V. Sampling dynamic networks with application to investigation of HIV epidemic drivers. Math Biosci. 2015 Sep; 267:124-33. PMID: 26200019.
    Citations:    Fields:    Translation:HumansPHPublic Health
  50. Novitsky V, Bussmann H, Okui L, Logan A, Moyo S, van Widenfelt E, Mmalane M, Lei Q, Holme MP, Makhema J, Lockman S, Degruttola V, Essex M. Estimated age and gender profile of individuals missed by a home-based HIV testing and counselling campaign in a Botswana community. J Int AIDS Soc. 2015; 18:19918. PMID: 26028155.
    Citations: 9     Fields:    Translation:HumansCells
  51. Shikuma CM, Bennett K, Ananworanich J, Gerschenson M, Teeratakulpisarn N, Jadwattanakul T, DeGruttola V, McArthur JC, Ebenezer G, Chomchey N, Praihirunkit P, Hongchookiat P, Mathajittiphun P, Nakamoto B, Hauer P, Phanuphak P, Phanuphak N. Distal leg epidermal nerve fiber density as a surrogate marker of HIV-associated sensory neuropathy risk: risk factors and change following initial antiretroviral therapy. J Neurovirol. 2015 Oct; 21(5):525-34. PMID: 26002840.
    Citations: 3     Fields:    Translation:HumansCells
  52. Novitsky V, Moyo S, Lei Q, DeGruttola V, Essex M. Importance of Viral Sequence Length and Number of Variable and Informative Sites in Analysis of HIV Clustering. AIDS Res Hum Retroviruses. 2015 May; 31(5):531-42. PMID: 25560745.
    Citations: 10     Fields:    Translation:HumansCells
  53. Lynch ML, DeGruttola V. Predicting time to threshold for initiating antiretroviral treatment to evaluate cost of treatment as prevention of human immunodeficiency virus. J R Stat Soc Ser C Appl Stat. 2015 02 01; 64(2):359-375. PMID: 25620814.
    Citations: 1     
  54. Novitsky V, Moyo S, Lei Q, DeGruttola V, Essex M. Impact of sampling density on the extent of HIV clustering. AIDS Res Hum Retroviruses. 2014 Dec; 30(12):1226-35. PMID: 25275430.
    Citations: 31     Fields:    Translation:HumansCells
  55. Wang R, Goyal R, Lei Q, Essex M, De Gruttola V. Sample size considerations in the design of cluster randomized trials of combination HIV prevention. Clin Trials. 2014 06; 11(3):309-318. PMID: 24651566.
    Citations: 14     Fields:    Translation:Humans
  56. Goyal R, De Gruttola V, Blitzstein J. Sampling Networks from Their Posterior Predictive Distribution. Netw Sci (Camb Univ Press). 2014 Apr 01; 2(1):107-131. PMID: 25339990.
    Citations: 7     
  57. Burns DN, DeGruttola V, Pilcher CD, Kretzschmar M, Gordon CM, Flanagan EH, Duncombe C, Cohen MS. Toward an endgame: finding and engaging people unaware of their HIV-1 infection in treatment and prevention. AIDS Res Hum Retroviruses. 2014 Mar; 30(3):217-24. PMID: 24410300.
    Citations: 19     Fields:    Translation:Humans
  58. Carnegie NB, Wang R, Novitsky V, De Gruttola V. Linkage of viral sequences among HIV-infected village residents in Botswana: estimation of linkage rates in the presence of missing data. PLoS Comput Biol. 2014 Jan; 10(1):e1003430. PMID: 24415932.
    Citations: 8     Fields:    Translation:HumansCellsPHPublic Health
  59. Stephens A, Tchetgen Tchetgen E, De Gruttola V. Locally efficient estimation of marginal treatment effects when outcomes are correlated: is the prize worth the chase? Int J Biostat. 2014; 10(1):59-75. PMID: 24566369.
    Citations: 2     Fields:    Translation:Humans
  60. Stephens AJ, Tchetgen Tchetgen EJ, De Gruttola V. FLEXIBLE COVARIATE-ADJUSTED EXACT TESTS OF RANDOMIZED TREATMENT EFFECTS WITH APPLICATION TO A TRIAL OF HIV EDUCATION. Ann Appl Stat. 2013 Dec 23; 7(4):2106-2137. PMID: 24587845.
    Citations: 2     
  61. Novitsky V, Bussmann H, Logan A, Moyo S, van Widenfelt E, Okui L, Mmalane M, Baca J, Buck L, Phillips E, Tim D, McLane MF, Lei Q, Wang R, Makhema J, Lockman S, DeGruttola V, Essex M. Phylogenetic relatedness of circulating HIV-1C variants in Mochudi, Botswana. PLoS One. 2013; 8(12):e80589. PMID: 24349005.
    Citations: 16     Fields:    Translation:HumansCells
  62. Rubin E, LaVange L, DeGruttola V. University of Pennsylvania 5th annual conference on statistical issues in clinical trials: emerging statistical issues in biomarker validation (afternoon session). Clin Trials. 2013 Oct; 10(5):701-8. PMID: 23988466.
    Citations:    Fields:    Translation:Humans
  63. Valcour VG, Ananworanich J, Agsalda M, Sailasuta N, Chalermchai T, Schuetz A, Shikuma C, Liang CY, Jirajariyavej S, Sithinamsuwan P, Tipsuk S, Clifford DB, Paul R, Fletcher JL, Marovich MA, Slike BM, DeGruttola V, Shiramizu B. HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients. PLoS One. 2013; 8(7):e70164. PMID: 23936155.
    Citations: 49     Fields:    Translation:HumansCells
  64. Izu A, Cohen T, Degruttola V. Bayesian estimation of mixture models with prespecified elements to compare drug resistance in treatment-naïve and experienced tuberculosis cases. PLoS Comput Biol. 2013; 9(3):e1002973. PMID: 23555210.
    Citations: 2     Fields:    Translation:HumansCells
  65. Chalermchai T, Valcour V, Sithinamsuwan P, Pinyakorn S, Clifford D, Paul RH, Tipsuk S, Fletcher JL, Degruttola V, Ratto-Kim S, Hutchings N, Shikuma C, Ananworanich J. Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. J Neurovirol. 2013 Apr; 19(2):137-43. PMID: 23483520.
    Citations: 8     Fields:    Translation:Humans
  66. Sailasuta N, Ross W, Ananworanich J, Chalermchai T, DeGruttola V, Lerdlum S, Pothisri M, Busovaca E, Ratto-Kim S, Jagodzinski L, Spudich S, Michael N, Kim JH, Valcour V. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One. 2012; 7(11):e49272. PMID: 23229129.
    Citations: 54     Fields:    Translation:HumansCellsCTClinical Trials
  67. Shikuma CM, Nakamoto B, Shiramizu B, Liang CY, DeGruttola V, Bennett K, Paul R, Kallianpur K, Chow D, Gavegnano C, Hurwitz SJ, Schinazi RF, Valcour VG. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012; 17(7):1233-42. PMID: 23018140.
    Citations: 34     Fields:    Translation:HumansCells
  68. Stitelman OM, De Gruttola V, van der Laan MJ. A general implementation of TMLE for longitudinal data applied to causal inference in survival analysis. Int J Biostat. 2012 Sep 18; 8(1). PMID: 22992289.
    Citations: 18     Fields:    Translation:Humans
  69. Stock S, DeGruttola V. Recursive partitioning for monotone missing at random longitudinal markers. Stat Med. 2013 Mar 15; 32(6):978-94. PMID: 22941582.
    Citations:    Fields:    Translation:HumansCells
  70. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012; 9(8):e1001290. PMID: 22936892.
    Citations: 66     Fields:    Translation:HumansCells
  71. Yang Y, DeGruttola V. Resampling-based methods in single and multiple testing for equality of covariance/correlation matrices. Int J Biostat. 2012 Jun 22; 8(1):Article 13. PMID: 22740584.
    Citations:    Fields:    Translation:HumansCells
  72. Wester CW, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, Hendrickson SL, Winkler CA, O'Brien SJ, Essex M, D'Aquila RT, DeGruttola V, Marlink RG. Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses. 2012 Aug; 28(8):759-65. PMID: 22540188.
    Citations: 9     Fields:    Translation:Humans
  73. Shikuma C, Gerschenson M, Ananworanich J, Valcour V, Teeratakulpisarn N, Jadwattanakul T, Degruttola V, Liang CY, McArthur J, Ebenezer G, Chomchey N, Praihirunkit P, Hongchookiath P, Mathajittiphun P, Nakamoto B, Hauer P, Phanuphak P, Phanuphak N. Determinants of epidermal nerve fibre density in antiretroviral-naïve HIV-infected individuals. HIV Med. 2012 Nov; 13(10):602-8. PMID: 22574621.
    Citations: 6     Fields:    Translation:HumansCells
  74. Goyal R, Wang R, DeGruttola V. Editorial commentary: network epidemic models: assumptions and interpretations. Clin Infect Dis. 2012 Jul; 55(2):276-8. PMID: 22491502.
    Citations: 2     Fields:    Translation:HumansCells
  75. Wester CW, Stitelman OM, deGruttola V, Bussmann H, Marlink RG, van der Laan MJ. Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. AIDS Res Hum Retroviruses. 2012 Sep; 28(9):981-8. PMID: 22309114.
    Citations: 1     Fields:    Translation:Humans
  76. Stephens AJ, Tchetgen Tchetgen EJ, De Gruttola V. Augmented generalized estimating equations for improving efficiency and validity of estimation in cluster randomized trials by leveraging cluster-level and individual-level covariates. Stat Med. 2012 May 10; 31(10):915-30. PMID: 22359361.
    Citations: 10     Fields:    Translation:Humans
  77. Lok JJ, DeGruttola V. Impact of time to start treatment following infection with application to initiating HAART in HIV-positive patients. Biometrics. 2012 Sep; 68(3):745-54. PMID: 22352840.
    Citations: 5     Fields:    Translation:Humans
  78. Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, Macatangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012 Jan 01; 205(1):87-96. PMID: 22180621.
    Citations: 36     Fields:    Translation:HumansCells
  79. Wertheim JO, Kosakovsky Pond SL, Little SJ, De Gruttola V. Using HIV transmission networks to investigate community effects in HIV prevention trials. PLoS One. 2011; 6(11):e27775. PMID: 22114692.
    Citations: 16     Fields:    Translation:HumansCells
  80. Shikuma CM, Seto T, Liang CY, Bennett K, DeGruttola V, Gerschenson M, Stein JH, Budoff M, Hodis HN, Delaney JA, Ogata-Arakaki D, Pramyothin P, Chow D. Vitamin D levels and markers of arterial dysfunction in HIV. AIDS Res Hum Retroviruses. 2012 Aug; 28(8):793-7. PMID: 21978287.
    Citations: 25     Fields:    Translation:Humans
  81. McCoy CB, De Gruttola V, Metsch L, Comerford M. A comparison of the efficacy of two interventions to reduce HIV risk behaviors among drug users. AIDS Behav. 2011 Nov; 15(8):1707-14. PMID: 21681563.
    Citations: 1     Fields:    Translation:Humans
  82. Novitsky V, Ndung'u T, Wang R, Bussmann H, Chonco F, Makhema J, De Gruttola V, Walker BD, Essex M. Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS. 2011 Jul 31; 25(12):1515-22. PMID: 21505307.
    Citations: 35     Fields:    Translation:HumansCells
  83. Merchant RC, Clark MA, Langan TJ, Mayer KH, Seage GR, DeGruttola VG. Can computer-based feedback improve emergency department patient uptake of rapid HIV screening? Ann Emerg Med. 2011 Jul; 58(1 Suppl 1):S114-9.e1-2. PMID: 21684389.
    Citations: 9     Fields:    Translation:HumansPHPublic Health
  84. Izu A, Cohen T, Mitnick C, Murray M, De Gruttola V. Bayesian methods for fitting mixture models that characterize branching tree processes: An application to development of resistant TB strains. Stat Med. 2011 Sep 30; 30(22):2708-20. PMID: 21717491.
    Citations: 1     Fields:    Translation:HumansCells
  85. Hu C, Degruttola V. Recursive partitioning of resistant mutations for longitudinal markers based on a U-type score. Biostatistics. 2011 Oct; 12(4):750-62. PMID: 21596729.
    Citations: 1     Fields:    Translation:HumansCells
  86. DeGruttola V, Schooley RT. Antiretroviral therapy as prevention: linking the mainframe to Main Street. Clin Infect Dis. 2011 Apr 15; 52(8):1050-2. PMID: 21460323.
    Citations: 2     Fields:    Translation:Humans
  87. Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis. 2011 Apr 01; 203(7):969-75. PMID: 21402548.
    Citations: 41     Fields:    Translation:Humans
  88. Stitelman OM, Wester CW, De Gruttola V, van der Laan MJ. Targeted maximum likelihood estimation of effect modification parameters in survival analysis. Int J Biostat. 2011 Mar 30; 7(1):19. PMID: 21556287.
    Citations: 4     Fields:    Translation:Humans
  89. Gezmu M, DeGruttola V, Dixon D, Essex M, Halloran E, Hogan J, Grobler A, Kim S, McDermott J, McKaig R, Neaton JD. Strengthening biostatistics resources in sub-Saharan Africa: research collaborations through U.S. partnerships. Stat Med. 2011 Mar 30; 30(7):695-708. PMID: 21394746.
    Citations: 10     Fields:    Translation:PHPublic Health
  90. Veronese F, Anton P, Fletcher CV, DeGruttola V, McGowan I, Becker S, Zwerski S, Burns D. Implications of HIV PrEP trials results. AIDS Res Hum Retroviruses. 2011 Jan; 27(1):81-90. PMID: 20969483.
    Citations: 8     Fields:    Translation:HumansCells
  91. Firnhaber C, Smeaton L, Saukila N, Flanigan T, Gangakhedkar R, Kumwenda J, La Rosa A, Kumarasamy N, De Gruttola V, Hakim JG, Campbell TB. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis. 2010 Dec; 14(12):e1088-92. PMID: 20961784.
    Citations: 29     Fields:    Translation:HumansCells
  92. Kolber MA, Buendia P, Degruttola V, Moore RD. HIV-1 diversity after a class switch failure. AIDS Res Hum Retroviruses. 2010 Nov; 26(11):1175-80. PMID: 20854203.
    Citations:    Fields:    Translation:HumansCells
  93. DeGruttola V, Smith DM, Little SJ, Miller V. Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S102-7. PMID: 20397937.
    Citations: 14     Fields:    Translation:HumansPHPublic Health
  94. Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, Thior I, Wester C, Wester CW, Ogwu A, Asmelash A, Musonda R, Campa A, Moyo S, van Widenfelt E, Mine M, Moffat C, Mmalane M, Makhema J, Marlink R, Gilbert P, Seage GR, DeGruttola V, Essex M. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. PLoS One. 2010 Apr 12; 5(4):e10148. PMID: 20405044.
    Citations: 31     Fields:    Translation:AnimalsCellsPHPublic Health
  95. Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D. Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. AIDS. 2010 Jan 28; 24(3):365-71. PMID: 19864933.
    Citations: 2     Fields:    Translation:HumansCells
  96. Tournoud M, Etard JF, Ecochard R, DeGruttola V. Adherence to antiretroviral therapy, virological response, and time to resistance in the Dakar cohort. Stat Med. 2010 Jan 15; 29(1):14-32. PMID: 19941299.
    Citations: 1     Fields:    Translation:HumansCells
  97. Wester CW, Thomas AM, Bussmann H, Moyo S, Makhema JM, Gaolathe T, Novitsky V, Essex M, deGruttola V, Marlink RG. Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. AIDS. 2010 Jan; 24 Suppl 1:S27-36. PMID: 20023437.
    Citations: 20     Fields:    Translation:HumansCells
  98. Merchant RC, Freelove SM, Langan TJ, Clark MA, Mayer KH, Seage GR, DeGruttola VG. The relationship of reported HIV risk and history of HIV testing among emergency department patients. Postgrad Med. 2010 Jan; 122(1):61-74. PMID: 20107290.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  99. Merchant RC, Clark MA, Langan TJ, Seage GR, Mayer KH, DeGruttola VG. Effectiveness of increasing emergency department patients' self-perceived risk for being human immunodeficiency virus (HIV) infected through audio computer self-interview-based feedback about reported HIV risk behaviors. Acad Emerg Med. 2009 Nov; 16(11):1143-55. PMID: 20053235.
    Citations: 9     Fields:    Translation:HumansPHPublic Health
  100. Buendia P, Cadwallader B, DeGruttola V. A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance. Bioinformatics. 2009 Oct 01; 25(19):2522-9. PMID: 19654117.
    Citations: 7     Fields:    Translation:Cells
  101. Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. . 2009 May 01; 51(1):37-46. PMID: 19282782.
    Citations: 26     Translation:HumansCells
  102. Merchant RC, Clark MA, Seage GR, Mayer KH, Degruttola VG, Becker BM. Emergency department patient perceptions and preferences on opt-in rapid HIV screening program components. AIDS Care. 2009 Apr; 21(4):490-500. PMID: 19283644.
    Citations: 16     Fields:    Translation:HumansPHPublic Health
  103. Valcour VG, Shiramizu BT, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, Ananworanich J, Siangphoe U, Kim JH, de Souza M, Degruttola V, Paul RH, Shikuma CM. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology. 2009 Mar 17; 72(11):992-8. PMID: 19289739.
    Citations: 41     Fields:    Translation:HumansCells
  104. Merchant RC, Catanzaro BM, Seage GR, Mayer KH, Clark MA, Degruttola VG, Becker BM. Demographic variations in HIV testing history among emergency department patients: implications for HIV screening in US emergency departments. J Med Screen. 2009; 16(2):60-6. PMID: 19564517.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  105. Merchant RC, Clark MA, Mayer KH, Seage Iii GR, DeGruttola VG, Becker BM. Video as an effective method to deliver pretest information for rapid human immunodeficiency testing. Acad Emerg Med. 2009 Feb; 16(2):124-35. PMID: 19120050.
    Citations: 13     Fields:    Translation:HumansPHPublic Health
  106. DeGruttola V, Little S, Schooley R. Controlling the HIV epidemic, without a vaccine! AIDS. 2008 Nov 30; 22(18):2554-5. PMID: 19005285.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  107. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, Puvimanasinghe J, Avalos A, Mine M, Seipone K, Essex M, Degruttola V, Marlink RG. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS. 2008 Nov 12; 22(17):2303-11. PMID: 18981769.
    Citations: 79     Fields:    Translation:HumansCells
  108. Merchant RC, Seage GR, Mayer KH, Clark MA, DeGruttola VG, Becker BM. Emergency department patient acceptance of opt-in, universal, rapid HIV screening. Public Health Rep. 2008 Nov-Dec; 123 Suppl 3:27-40. PMID: 19172704.
    Citations: 34     Fields:    Translation:HumansPHPublic Health
  109. Schumi J, Degruttola V. Resampling-based analyses of the effects of combinations of HIV genetic mutations on drug susceptibility. Stat Med. 2008 Oct 15; 27(23):4740-57. PMID: 18186529.
    Citations: 2     Fields:    Translation:Humans
  110. Schumi J, DiRienzo AG, DeGruttola V. Testing for associations with missing high-dimensional categorical covariates. Int J Biostat. 2008 Sep 29; 4(1):Article 18. PMID: 20231909.
    Citations:    Fields:    Translation:HumansCells
  111. Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola D. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 2008 Aug 15; 198(4):470-80. PMID: 18598191.
    Citations: 5     Fields:    Translation:HumansCells
  112. Tai BC, De Stavola BL, de Gruttola V, Gebski V, Machin D. First-event or marginal estimation of cause-specific hazards for analysing correlated multivariate failure-time data? Stat Med. 2008 Mar 15; 27(6):922-36. PMID: 17551931.
    Citations: 3     Fields:    Translation:Humans
  113. Healy BC, DeGruttola VG, Hu C. Accommodating uncertainty in a tree set for function estimation. Stat Appl Genet Mol Biol. 2008; 7(1):Article5. PMID: 18312210.
    Citations: 1     Fields:    Translation:HumansCells
  114. Spritzler J, DeGruttola VG, Pei L. Two-sample tests of area-under-the-curve in the presence of missing data. Int J Biostat. 2008 Jan 17; 4(1):Article 1. PMID: 20231907.
    Citations: 3     Fields:    Translation:Humans
  115. Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S, Squires K. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials. 2008 Jan-Feb; 9(1):11-25. PMID: 18215978.
    Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
  116. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T, Makhema J, van Widenfelt E, Musonda R, Novitsky V, Gaolathe T, Ndwapi N, Essex M, Kuritzkes DR, DeGruttola V, Marlink RG. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr. 2007 Nov 01; 46(3):318-22. PMID: 18090299.
    Citations: 36     Fields:    Translation:Humans
  117. Yang Y, Degruttola V. Resampling-based multiple testing methods with covariate adjustment: application to investigation of antiretroviral drug susceptibility. Biometrics. 2008 Jun; 64(2):329-36. PMID: 17900313.
    Citations:    Fields:    Translation:Cells
  118. Merchant RC, Gee EM, Clark MA, Mayer KH, Seage GR, Degruttola VG. Comparison of patient comprehension of rapid HIV pre-test fundamentals by information delivery format in an emergency department setting. BMC Public Health. 2007 Sep 12; 7:238. PMID: 17850670.
    Citations: 18     Fields:    Translation:Humans
  119. Vaida F, Fitzgerald AP, Degruttola V. Efficient Hybrid EM for Linear and Nonlinear Mixed Effects Models with Censored Response. Comput Stat Data Anal. 2007 Aug 15; 51(12):5718-5730. PMID: 19578533.
    Citations: 13     
  120. Novitsky V, Wester CW, DeGruttola V, Bussmann H, Gaseitsiwe S, Thomas A, Moyo S, Musonda R, Van Widenfelt E, Marlink RG, Essex M. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses. 2007 Jul; 23(7):868-78. PMID: 17678469.
    Citations: 34     Fields:    Translation:HumansCells
  121. Healy B, De Gruttola V, Pagano M. Combining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations. Biometrics. 2007 Sep; 63(3):742-50. PMID: 17403101.
    Citations:    Fields:    Translation:Cells
  122. Hu C, De Gruttola V. Joint modeling of progression of HIV resistance mutations measured with uncertainty and failure time data. Biometrics. 2007 Mar; 63(1):60-8. PMID: 17447930.
    Citations: 1     Fields:    Translation:Cells
  123. May S, Degruttola V. Nonparametric tests for two-group comparisons of dependent observations obtained at varying time points. Biometrics. 2007 Mar; 63(1):194-200. PMID: 17447945.
    Citations: 2     Fields:    Translation:HumansCells
  124. Foulkes AS, DeGruttola VG. A resampling-based approach to multiple testing with uncertainty in phase. Int J Biostat. 2007; 3(1):Article 2. PMID: 22550644.
    Citations: 1     Fields:    Translation:HumansCells
  125. Suruki RY, Mueller N, Hayashi K, Harn D, DeGruttola V, Raker CA, Tsubouchi H, Stuver SO. Host immune status and incidence of hepatocellular carcinoma among subjects infected with hepatitis C virus: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2521-5. PMID: 17164379.
    Citations: 6     Fields:    Translation:HumansCells
  126. De Gruttola V, Flexner C, Schapiro J, Hughes M, Van Der Laan M, Kuritzkes DR. Drug development strategies for salvage therapy: conflicts and solutions. AIDS Res Hum Retroviruses. 2006 Nov; 22(11):1106-9. PMID: 17147496.
    Citations:    Fields:    Translation:Humans
  127. Healy B, Degruttola V. Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses. Biostatistics. 2007 Apr; 8(2):438-52. PMID: 16940036.
    Citations: 3     Fields:    Translation:HumansCells
  128. Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, Cohen D, Pae E, Davis B, Zachary K, Basgoz N, D'agata EM, DeGruttola V, Walker BD, Rosenberg ES. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006 Apr 01; 42(7):1024-31. PMID: 16511771.
    Citations: 25     Fields:    Translation:HumansCells
  129. De Gruttola S, Boomsma K, Poulikakos D. Computational simulation of a non-newtonian model of the blood separation process. Artif Organs. 2005 Dec; 29(12):949-59. PMID: 16305650.
    Citations: 4     Fields:    Translation:HumansCells
  130. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Donahue JP, Kim RB. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 01; 192(11):1931-42. PMID: 16267764.
    Citations: 95     Fields:    Translation:Humans
  131. Brown ER, Ibrahim JG, DeGruttola V. A flexible B-spline model for multiple longitudinal biomarkers and survival. Biometrics. 2005 Mar; 61(1):64-73. PMID: 15737079.
    Citations: 40     Fields:    Translation:Humans
  132. De Gruttola V, Foulkes AS. Validation and discovery in Markov models of genetics data. Stat Appl Genet Mol Biol. 2004; 3:Article38. PMID: 16646818.
    Citations: 1     Fields:    
  133. Brun-Vézinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther. 2004 Aug; 9(4):465-78. PMID: 15456077.
    Citations: 18     Fields:    Translation:HumansCells
  134. Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004 May 15; 189(10):1811-20. PMID: 15122517.
    Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
  135. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11; 349(24):2304-15. PMID: 14668456.
    Citations: 57     Fields:    Translation:HumansCellsCTClinical Trials
  136. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11; 349(24):2293-303. PMID: 14668455.
    Citations: 91     Fields:    Translation:HumansCellsCTClinical Trials
  137. Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003 Dec; 8(6):507-18. PMID: 14760884.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  138. Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzenstein D, Albrecht M, DeGruttola V. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003 Oct 01; 188(7):1001-8. PMID: 14513420.
    Citations: 8     Fields:    Translation:HumansCells
  139. DiRienzo AG, DeGruttola V, Larder B, Hertogs K. Non-parametric methods to predict HIV drug susceptibility phenotype from genotype. Stat Med. 2003 Sep 15; 22(17):2785-98. PMID: 12939786.
    Citations: 10     Fields:    Translation:HumansCells
  140. Foulkes AS, DeGruttola V. Characterizing classes of antiretroviral drugs by genotype. Stat Med. 2003 Aug 30; 22(16):2637-55. PMID: 12898549.
    Citations: 2     Fields:    Translation:HumansCells
  141. Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis. 2003 Jul 15; 188(2):179-93. PMID: 12854072.
    Citations: 11     Fields:    Translation:HumansCells
  142. DiRienzo AG, DeGruttola V. Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142. Control Clin Trials. 2003 Apr; 24(2):122-34. PMID: 12689734.
    Citations: 2     Fields:    Translation:Humans
  143. Izazola-Licea JA, Gortmaker SL, de Gruttola V, Tolbert K, Mann J. Sexual behavior patterns and HIV risks in bisexual men compared to exclusively heterosexual and homosexual men. Salud Publica Mex. 2003; 45 Supp 5:S662-71. PMID: 14974278.
    Citations: 5     Fields:    Translation:Humans
  144. Bennett KK, DeGruttola VG, Marschner IC, Havlir DV, Richman DD. Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. . 2002 Sep 01; 31(1):20-6. PMID: 12352146.
    Citations: 11     Translation:HumansCellsCTClinical Trials
  145. Fitzgerald AP, DeGruttola VG, Vaida F. Modelling HIV viral rebound using non-linear mixed effects models. Stat Med. 2002 Jul 30; 21(14):2093-108. PMID: 12111889.
    Citations: 8     Fields:    Translation:HumansCells
  146. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002 Jul 10; 288(2):169-80. PMID: 12095381.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  147. Nokta MA, Holland F, De Gruttola V, Emery VC, Jacobson MA, Griffiths P, Pollard RB, Feinberg JE. Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease. J Infect Dis. 2002 Jun 15; 185(12):1717-22. PMID: 12085316.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  148. Foulkes AS, De GV. Characterizing the relationship between HIV-1 genotype and phenotype: prediction-based classification. Biometrics. 2002 Mar; 58(1):145-56. PMID: 11890310.
    Citations: 9     Fields:    Translation:HumansCells
  149. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials. 2001 Oct; 22(5):485-502. PMID: 11578783.
    Citations: 89     Fields:    Translation:HumansCells
  150. Huang W, De Gruttola V, Fischl M, Hammer S, Richman D, Havlir D, Gulick R, Squires K, Mellors J. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. J Infect Dis. 2001 May 15; 183(10):1455-65. PMID: 11319681.
    Citations: 8     Fields:    Translation:HumansCells
  151. Smeaton LM, DeGruttola V, Robbins GK, Shafer RW. ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. Control Clin Trials. 2001 Apr; 22(2):142-59. PMID: 11306153.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  152. Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DR. Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA. 2001 Feb 14; 285(6):777-84. PMID: 11176916.
    Citations: 3     Fields:    Translation:Humans
  153. Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, Rosandich M. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis. 2000 Nov; 182(5):1357-64. PMID: 11023459.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  154. Gilbert PB, Hanna GJ, De Gruttola V, Martinez-Picado J, Kuritzkes DR, Johnson VA, Richman DD, D'Aquila RT. Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens. AIDS Res Hum Retroviruses. 2000 Sep 20; 16(14):1325-36. PMID: 11018852.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  155. Sevin AD, DeGruttola V, Nijhuis M, Schapiro JM, Foulkes AS, Para MF, Boucher CA. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. J Infect Dis. 2000 Jul; 182(1):59-67. PMID: 10882582.
    Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
  156. Kim S, Hughes MD, Hammer SM, Jackson JB, DeGruttola V, Katzenstein DA. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. AIDS Res Hum Retroviruses. 2000 May 01; 16(7):645-53. PMID: 10791875.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  157. Litwack RS, Gilligan DM, DeGruttola V. Beta-blockade for patients undergoing vascular surgery. N Engl J Med. 2000 Apr 06; 342(14):1052; author reply 1052-3. PMID: 10755897.
    Citations:    Fields:    Translation:Humans
  158. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000 Mar; 5(1):41-8. PMID: 10846592.
    Citations: 57     Fields:    Translation:HumansCells
  159. Izazola-Licea JA, Gortmaker SL, De Gruttola V, Tolbert K, Mann J. Assessment of non-response bias in a probability household survey of male same-gender sexual behavior. Salud Publica Mex. 2000 Mar-Apr; 42(2):90-8. PMID: 10893978.
    Citations:    Fields:    Translation:Humans
  160. Goebel FD, Mannhalter JW, Belshe RB, Eibl MM, Grob PJ, de Gruttola V, Griffiths PD, Erfle V, Kunschak M, Engl W. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group. AIDS. 1999 Aug 20; 13(12):1461-8. PMID: 10465068.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  161. Kim S, De Gruttola V. Strategies for cohort sampling under the Cox proportional hazards model, application to an AIDS clinical trial. Lifetime Data Anal. 1999 Jun; 5(2):149-72. PMID: 10408182.
    Citations: 3     Fields:    Translation:Humans
  162. Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R, Kuritzkes DR. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis. 1999 Apr; 179(4):808-16. PMID: 10068575.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  163. Marschner IC, Betensky RA, DeGruttola V, Hammer SM, Kuritzkes DR. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 01; 20(3):220-7. PMID: 10077169.
    Citations: 9     Fields:    Translation:HumansCells
  164. Wu H, Ding AA, De Gruttola V. Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? AIDS. 1999 Feb 25; 13(3):429-30. PMID: 10199240.
    Citations: 2     Fields:    Translation:HumansCells
  165. Wu H, Ding AA, De Gruttola V. Estimation of HIV dynamic parameters. Stat Med. 1998 Nov 15; 17(21):2463-85. PMID: 9819839.
    Citations: 25     Fields:    Translation:Humans
  166. Litwack RS, DeGruttola V. Predicting long-term postoperative cardiovascular outcomes. Anesthesiology. 1998 Nov; 89(5):1286-8. PMID: 9822031.
    Citations:    Fields:    Translation:Humans
  167. Gilbert P, DeGruttola V, Hammer S. Efficient trial designs for studying combination antiretroviral treatments in patients with various resistance profiles. J Infect Dis. 1998 Aug; 178(2):340-8. PMID: 9697713.
    Citations: 1     Fields:    Translation:Humans
  168. Zackin R, Marschner I, Andersen J, Cowles MK, De Gruttola V, Hammer S, Fischl M, Cotton D. Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping. J Infect Dis. 1998 Mar; 177(3):761-5. PMID: 9498459.
    Citations:    Fields:    Translation:HumansCells
  169. DeGruttola V, Hughes M, Gilbert P, Phillips A. Trial design in the era of highly effective antiviral drug combinations for HIV infection. AIDS. 1998; 12 Suppl A:S149-56. PMID: 9632997.
    Citations: 3     Fields:    Translation:HumansCells
  170. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998 Jan; 177(1):40-7. PMID: 9419168.
    Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
  171. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1997 Jul 15; 16(13):1515-27. PMID: 9249922.
    Citations: 152     Fields:    Translation:Humans
  172. Mildvan D, Landay A, De Gruttola V, Machado SG, Kagan J. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis. 1997 May; 24(5):764-74. PMID: 9142767.
    Citations: 18     Fields:    Translation:Humans
  173. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers--are we being naive? J Infect Dis. 1997 Feb; 175(2):237-46. PMID: 9203643.
    Citations: 19     Fields:    Translation:Humans
  174. Fleming TR, DeGruttola V, DeMets DL. Surrogate endpoints. AIDS Clin Rev. 1997-1998; 129-43. PMID: 9305447.
    Citations: 1     Fields:    Translation:Humans
  175. LaValley MP, DeGruttola V. Models for empirical Bayes estimators of longitudinal CD4 counts. Stat Med. 1996 Nov 15-30; 15(21-22):2289-305; discussion 2337-40. PMID: 8931202.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  176. Cohen CJ, Hellinger JA, Day J, Salitsky N, Shevitz A, Zackin R, DeGruttola V. Lack of effect of cimetidine on lymphocyte subsets in patients infected with human immunodeficiency virus type 1. Clin Infect Dis. 1996 Nov; 23(5):1049-54. PMID: 8922801.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  177. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996 Oct; 174(4):704-12. PMID: 8843206.
    Citations: 27     Fields:    Translation:HumansCells
  178. De Gruttola V, Fleming T, Coombs R. Viral load and response to treatment of HIV. N Engl J Med. 1996 Jun 20; 334(25):1671-2; author reply 1672-3. PMID: 8628373.
    Citations:    Fields:    Translation:HumansCells
  179. Jacobson MA, De Gruttola V, Reddy M, Arduino JM, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC, et al. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. AIDS. 1995 Jul; 9(7):727-34. PMID: 7546418.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  180. Ragni MV, Amato DA, LoFaro ML, DeGruttola V, Van Der Horst C, Eyster ME, Kessler CM, Gjerset GF, Ho M, Parenti DM, et al. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups. Blood. 1995 May 01; 85(9):2337-46. PMID: 7727768.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  181. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med. 1995 Mar 15; 122(6):401-8. PMID: 7856987.
    Citations: 54     Fields:    Translation:HumansCellsCTClinical Trials
  182. Fiscus SA, DeGruttola V, Gupta P, Katzenstein DA, Meyer WA, LoFaro ML, Katzman M, Ragni MV, Reichelderfer PS, Coombs RW. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis. 1995 Feb; 171(2):305-11. PMID: 7844365.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  183. Hughes MD, DeGruttola V, Welles SL. Evaluating surrogate markers. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 Suppl 2:S1-8. PMID: 7552506.
    Citations: 6     Fields:    Translation:Humans
  184. Pagano M, Tu XM, De Gruttola V, MaWhinney S. Regression analysis of censored and truncated data: estimating reporting-delay distributions and AIDS incidence from surveillance data. Biometrics. 1994 Dec; 50(4):1203-14. PMID: 7787003.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  185. De Gruttola V, Tu XM. Modelling progression of CD4-lymphocyte count and its relationship to survival time. Biometrics. 1994 Dec; 50(4):1003-14. PMID: 7786983.
    Citations: 58     Fields:    Translation:Humans
  186. Gauvreau K, Degruttola V, Pagano M, Bellocco R. The effect of covariates on the induction time of AIDS using improved imputation of exact seroconversion times. Stat Med. 1994 Oct 15-30; 13(19-20):2021-30. PMID: 7846407.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  187. DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH, Rasheed S, Hollinger FB, Fischl MA, Volberding P. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. J Infect Dis. 1994 Apr; 169(4):713-21. PMID: 8133085.
    Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
  188. De Gruttola V, Gelman R, Lagakos S. Uses of CD4-lymphocyte count in AIDS treatment decisions. Infect Agents Dis. 1993 Oct; 2(5):304-13. PMID: 7909710.
    Citations: 2     Fields:    Translation:HumansCells
  189. De Gruttola V, Wulfsohn M, Fischl MA, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr (1988). 1993 Apr; 6(4):359-65. PMID: 8095980.
    Citations: 16     Translation:HumansCellsCTClinical Trials
  190. Kim MY, De Gruttola VG, Lagakos SW. Analyzing doubly censored data with covariates, with application to AIDS. Biometrics. 1993 Mar; 49(1):13-22. PMID: 8513098.
    Citations: 13     Fields:    Translation:Humans
  191. Mohar A, De Gruttola V, Mueller N, Sepúlveda J. A model for the AIDS epidemic in Mexico: short-term projections. J Acquir Immune Defic Syndr (1988). 1992; 5(3):265-70. PMID: 1740752.
    Citations:    Translation:HumansPHPublic Health
  192. Byar DP, Schoenfeld DA, Green SB, Amato DA, Davis R, De Gruttola V, Finkelstein DM, Gatsonis C, Gelber RD, Lagakos S, et al. Design considerations for AIDS trials. N Engl J Med. 1990 Nov 08; 323(19):1343-8. PMID: